Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
- DOI
- 10.1016/j.ejca.2010.07.021
- Published
- 2010 Nov
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2010.07.021,
title = {Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.},
author = {Ortholan C and Durivault J and Hannoun-Levi JM and Guyot M and Bourcier C and Ambrosetti D and Safe S and Pagès G},
year = {2010},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2010.07.021},
url = {https://doi.org/10.1016/j.ejca.2010.07.021}
}RIS
TY - JOUR TI - Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. AU - Ortholan C AU - Durivault J AU - Hannoun-Levi JM AU - Guyot M AU - Bourcier C AU - Ambrosetti D AU - Safe S AU - Pagès G PY - 2010 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2010.07.021 UR - https://doi.org/10.1016/j.ejca.2010.07.021 ER -
APA
C, O., J, D., JM, H., M, G., C, B., D, A., S, S., & G, P. (2010). Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2010.07.021
Source records
- pubmed · retrieved 2026-11-10T16:46:25.832Z
- europe-pmc · retrieved 2026-11-10T16:46:25.817Z
- hal · retrieved 2026-11-10T16:46:25.898Z